{"id":"NCT00590577","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2008-01-10","resultsPosted":"2009-10-05","lastUpdate":"2014-06-04"},"enrollment":652,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Paliperidone palmitate 25 mg eq.","otherNames":[]},{"type":"DRUG","name":"Paliperidone palmitate 150 mg eq.","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Paliperidone palmitate 100 mg eq.","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"EXPERIMENTAL"},{"label":"003","type":"EXPERIMENTAL"},{"label":"004","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of this study are to evaluate the efficacy and safety of 3 fixed doses of paliperidone palmitate administered i.m. after an initial loading dose of 150 mg eq. in the deltoid muscle followed by either deltoid or gluteal injections for a total of 13 weeks of treatment as compared with placebo in patients with schizophrenia.","primaryOutcome":{"measure":"Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 13 or the Last Post-baseline Assessment","timeFrame":"Baseline to 13 weeks or the last post-baseline assessment","effectByArm":[{"arm":"Paliperidone Palmitate 25 mg eq.","deltaMin":-8,"sd":19.9},{"arm":"Paliperidone Palmitate 100 mg eq.","deltaMin":-11.6,"sd":17.63},{"arm":"Paliperidone Palmitate 150 mg eq.","deltaMin":-13.2,"sd":18.48},{"arm":"Placebo","deltaMin":-2.9,"sd":19.26}],"pValues":[{"comp":"OG002 vs OG003","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG003","p":"0.034"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":20},"locations":{"siteCount":66,"countries":["United States","Malaysia","Romania","Russia","Serbia","South Korea","Taiwan","Ukraine"]},"refs":{"pmids":["24754314","21569242","21481243","20473057"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=64&filename=CR012550_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":15},"commonTop":["Headache","Injection site pain","Akathisia"]}}